BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Masi G, Vasile E, Loupakis F, Cupini S, Fornaro L, Baldi G, Salvatore L, Cremolini C, Stasi I, Brunetti I. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst. 2011;103:21-30. [PMID: 21123833 DOI: 10.1093/jnci/djq456] [Cited by in Crossref: 105] [Cited by in F6Publishing: 91] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Bruera G, Ricevuto E. Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy: Evaluation of Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845-52. Expert Opinion on Biological Therapy 2011;11:821-4. [DOI: 10.1517/14712598.2011.582462] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
2 Villard C, Habib M, Nordenvall C, Nilsson PJ, Jorns C, Sparrelid E. Conversion therapy in patients with colorectal liver metastases. Eur J Surg Oncol 2021;47:2038-45. [PMID: 33640172 DOI: 10.1016/j.ejso.2021.02.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Biller LH, Schrag D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review.JAMA. 2021;325:669-685. [PMID: 33591350 DOI: 10.1001/jama.2021.0106] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
4 Connor AA, Burkes R, Gallinger S. Strategies in the Multidisciplinary Management of Synchronous Colorectal Cancer and Resectable Liver Metastases. Curr Colorectal Cancer Rep 2014;10:227-38. [DOI: 10.1007/s11888-014-0222-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
5 Rivard JD, McConnell YJ, Temple WJ, Mack LA. Cytoreduction and heated intraperitoneal chemotherapy for colorectal cancer: are we excluding patients who may benefit? J Surg Oncol. 2014;109:104-109. [PMID: 24449172 DOI: 10.1002/jso.23446] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
6 Bjørnelv GMW, Dueland S, Line PD, Joranger P, Fretland ÅA, Edwin B, Sørbye H, Aas E. Cost-effectiveness of liver transplantation in patients with colorectal metastases confined to the liver. Br J Surg 2019;106:132-41. [PMID: 30325494 DOI: 10.1002/bjs.10962] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
7 Chen H, Zhang J, Cao G, Liu P, Xu H, Wang X, Zhu X, Gao S, Guo J, Zhu L, Zhang P. Target hepatic artery regional chemotherapy and bevacizumab perfusion in liver metastatic colorectal cancer after failure of first-line or second-line systemic chemotherapy. Anticancer Drugs 2016;27:118-26. [PMID: 26566233 DOI: 10.1097/CAD.0000000000000290] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
8 Dueland S, Guren TK, Hagness M, Glimelius B, Line PD, Pfeiffer P, Foss A, Tveit KM. Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer? Ann Surg. 2015;261:956-960. [PMID: 24950280 DOI: 10.1097/sla.0000000000000786] [Cited by in Crossref: 85] [Cited by in F6Publishing: 29] [Article Influence: 12.1] [Reference Citation Analysis]
9 Fornaro L, Lonardi S, Masi G, Loupakis F, Bergamo F, Salvatore L, Cremolini C, Schirripa M, Vivaldi C, Aprile G. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol. 2013;24:2062-2067. [PMID: 23666916 DOI: 10.1093/annonc/mdt165] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 7.4] [Reference Citation Analysis]
10 Reddy SK, Kesmodel SB, Alexander HR. Isolated hepatic perfusion for patients with liver metastases. Ther Adv Med Oncol. 2014;6:180-194. [PMID: 25057304 DOI: 10.1177/1758834014529175] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
11 Folprecht G. Neoadjuvant chemotherapy for non-/resectable metastases. European Journal of Cancer 2011;47:S52-60. [DOI: 10.1016/s0959-8049(11)70147-2] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
12 Min ST, Roohullah A, Tognela A, Jalali A, Lee M, Wong R, Shapiro J, Burge M, Yip D, Nott L, Zimet A, Lee B, Dean A, Steel S, Wong HL, Gibbs P, Lim SH. Patient demographics and management landscape of metastatic colorectal cancer in the third-line setting: Real-world data in an australian population. Asia Pac J Clin Oncol 2021. [PMID: 33870631 DOI: 10.1111/ajco.13553] [Reference Citation Analysis]
13 Volovat SR, Volovat C, Negru SM, Danciu M, Scripcariu V. The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis. J Chemother 2016;28:235-41. [PMID: 26018108 DOI: 10.1179/1973947815Y.0000000042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Lanari J, Hagness M, Sartori A, Rosso E, Gringeri E, Dueland S, Cillo U, Line PD. Liver transplantation versus liver resection for colorectal liver metastasis: a survival benefit analysis in patients stratified according to tumor burden score. Transpl Int 2021;34:1722-32. [PMID: 34448271 DOI: 10.1111/tri.13981] [Reference Citation Analysis]
15 Saleh K, Khalife-Saleh N, Kourie HR, Chahine G. How and when adjuvant treatment should be intensified in stage III colorectal cancers? Future Oncol. 2017;. [PMID: 28829195 DOI: 10.2217/fon-2017-0197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
16 Puia-Negulescu S, Lebossé F, Mabrut JY, Muller X, Rossignol G, Antonini T, Erard D, Radenne S, Guillet M, Souquet JC, Mohkam K, Lesurtel M. Liver Transplantation for Colorectal Liver Metastases: Current Management and Future Perspectives. Int J Mol Sci 2021;22:3093. [PMID: 33803503 DOI: 10.3390/ijms22063093] [Reference Citation Analysis]
17 Zoccali C, Skoch J, Walter CM, Torabi M, Borgstrom M, Baaj AA. The Tokuhashi score: effectiveness and pitfalls.Eur Spine J. 2016;25:673-678. [PMID: 26626082 DOI: 10.1007/s00586-015-4339-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
18 Bruera G, Cannita K, Giordano AV, Vicentini R, Ficorella C, Ricevuto E. Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients. Biomed Res Int 2013;2013:143273. [PMID: 24307987 DOI: 10.1155/2013/143273] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
19 García-Alfonso P, Torres G, García G, Gallego I, Ortega L, Sandoval C, Muñoz A, Lloansí A. FOLFOXIRI plus biologics in advanced colorectal cancer. Expert Opin Biol Ther 2019;19:411-22. [PMID: 30887844 DOI: 10.1080/14712598.2019.1595580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
20 Artaç M, Coşkun HŞ, Dane F, Karabulut B, Korkmaz L, Karaağaç M, Çabuk D, Karabulut S, Faruk Aykan N, Doruk H, Avcı N, Turhal NS. Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study. J Gastrointest Cancer 2016;47:264-72. [PMID: 27126591 DOI: 10.1007/s12029-016-9823-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
21 Essadi I, Sbitti Y, Fetohi M, Slimani KA, Essadi M, Tazi E, Ichou M, Errihani H. Treatment of Liver Metastases From Colorectal Cancer: Medico-Surgical Strategies. Gastroenterology Res 2011;4:122-4. [PMID: 27942326 DOI: 10.4021/gr317e] [Reference Citation Analysis]
22 Moris D, Tsilimigras DI, Chakedis J, Beal EW, Felekouras E, Vernadakis S, Schizas D, Fung JJ, Pawlik TM. Liver transplantation for unresectable colorectal liver metastases: A systematic review. J Surg Oncol. 2017;116:288-297. [PMID: 28513862 DOI: 10.1002/jso.24671] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
23 Ciombor KK, Berlin J. Targeting metastatic colorectal cancer - present and emerging treatment options. Pharmgenomics Pers Med 2014;7:137-44. [PMID: 25045279 DOI: 10.2147/PGPM.S47582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
24 Temraz S, Mukherji D, Shamseddine A. Sequencing of treatment in metastatic colorectal cancer: Where to fit the target? World J Gastroenterol 2014; 20(8): 1993-2004 [PMID: 24616571 DOI: 10.3748/wjg.v20.i8.1993] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
25 Glimelius B, Cavalli-Björkman N. Metastatic colorectal cancer: current treatment and future options for improved survival. Medical approach--present status. Scand J Gastroenterol 2012;47:296-314. [PMID: 22242568 DOI: 10.3109/00365521.2012.640828] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
26 Frühling P, Urdzik J, Strömberg C, Isaksson B. Composite Score: prognostic tool to predict survival in patients undergoing surgery for colorectal liver metastases. BJS Open 2021;5:zrab104. [PMID: 34697642 DOI: 10.1093/bjsopen/zrab104] [Reference Citation Analysis]
27 Gallinger S, Biagi JJ, Fletcher GG, Nhan C, Ruo L, McLeod RS. Liver resection for colorectal cancer metastases. Curr Oncol. 2013;20:e255-e265. [PMID: 23737695 DOI: 10.3747/co.20.1341] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
28 Sunakawa Y, Fujita K, Ichikawa W, Ishida H, Yamashita K, Araki K, Miwa K, Kawara K, Akiyama Y, Yamamoto W, Nagashima F, Saji S, Sasaki Y. A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28. Oncology 2012;82:242-8. [PMID: 22508373 DOI: 10.1159/000337225] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
29 Chau I, Joulain F, Iqbal SU, Bridgewater J. A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI. BMC Cancer. 2014;14:605. [PMID: 25142418 DOI: 10.1186/1471-2407-14-605] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
30 Ikoma N, Raghav K, Chang G. An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma. Surg Oncol Clin N Am. 2017;26:667-687. [PMID: 28923224 DOI: 10.1016/j.soc.2017.05.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
31 Sunakawa Y, Schirripa M, Lenz HJ. Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer. Crit Rev Oncol Hematol 2016;100:117-26. [PMID: 26850575 DOI: 10.1016/j.critrevonc.2016.01.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
32 Weickhardt A, Wells K, Messersmith W. Oxaliplatin-induced neuropathy in colorectal cancer. J Oncol. 2011;2011:201593. [PMID: 22203844 DOI: 10.1155/2011/201593] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
33 Kemeny NE. Treatment of metastatic colon cancer: "the times they are A-changing". J Clin Oncol 2013;31:1913-6. [PMID: 23630214 DOI: 10.1200/JCO.2013.49.4500] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
34 Glinka J, Ardiles V, Pekolj J, Mattera J, Sanchez Clariá R, de Santibañes E, de Santibañes M. Liver transplantation for non-resectable colorectal liver metastasis: where we are and where we are going. Langenbecks Arch Surg 2020;405:255-64. [PMID: 32333096 DOI: 10.1007/s00423-020-01883-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Zanetto A, Shalaby S, Gambato M, Germani G, Senzolo M, Bizzaro D, Russo FP, Burra P. New Indications for Liver Transplantation. J Clin Med 2021;10:3867. [PMID: 34501314 DOI: 10.3390/jcm10173867] [Reference Citation Analysis]
36 Ficorella C, Bruera G, Cannita K, Porzio G, Baldi PL, Tinari N, Natoli C, Ricevuto E. Triplet chemotherapy in patients with metastatic colorectal cancer: toward the best way to safely administer a highly active regimen in clinical practice. Clin Colorectal Cancer 2012;11:229-37. [PMID: 22694897 DOI: 10.1016/j.clcc.2012.05.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
37 Goey KK, 't Lam-boer J, de Wilt JH, Punt CJ, van Oijen MG, Koopman M. Significant increase of synchronous disease in first-line metastatic colorectal cancer trials: Results of a systematic review. European Journal of Cancer 2016;69:166-77. [DOI: 10.1016/j.ejca.2016.09.028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
38 Doussot A, Kemeny NE, D'Angelica MI. Hepatic arterial infusional chemotherapy in the management of colorectal cancer liver metastases. Hepat Oncol 2015;2:275-90. [PMID: 30191008 DOI: 10.2217/hep.15.9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
39 Bruera G, Cannita K, Giordano AV, Vicentini R, Ficorella C, Ricevuto E. Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype. Int J Oncol 2014;44:17-26. [PMID: 24247407 DOI: 10.3892/ijo.2013.2179] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
40 Sastre J, Orden V, Martínez A, Bando I, Balbín M, Bellosillo B, Palanca S, Peligros Gomez MI, Mediero B, Llovet P, Moral VM, Viéitez JM, García-Alfonso P, Calle SG, Ortiz-Morales MJ, Salud A, Quintero G, Lopez C, Díaz-Rubio E, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected. Clin Colorectal Cancer 2020;19:e110-6. [PMID: 32278676 DOI: 10.1016/j.clcc.2020.02.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
41 Gustavsson B. Simultaneous surgery for primary colorectal cancer and metastatic lesions? Scandinavian Journal of Gastroenterology 2011;47:269-76. [DOI: 10.3109/00365521.2012.640824] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
42 Khan K, Wale A, Brown G, Chau I. Colorectal cancer with liver metastases: Neoadjuvant chemotherapy, surgical resection first or palliation alone? World J Gastroenterol 2014; 20(35): 12391-12406 [PMID: 25253940 DOI: 10.3748/wjg.v20.i35.12391] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
43 Dueland S, Hagness M, Line P, Guren TK, Tveit KM, Foss A. Is Liver Transplantation an Option in Colorectal Cancer Patients with Nonresectable Liver Metastases and Progression on All Lines of Standard Chemotherapy? Ann Surg Oncol 2015;22:2195-200. [DOI: 10.1245/s10434-014-4137-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
44 Karanicolas PJ, Metrakos P, Chan K, Asmis T, Chen E, Kingham TP, Kemeny N, Porter G, Fields RC, Pingpank J. Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: expert consensus statement. Curr Oncol. 2014;21:e129-e136. [PMID: 24523610 DOI: 10.3747/co.21.1577] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
45 Bruera G, Cannita K, Di Giacomo D, Lamy A, Frébourg T, Sabourin JC, Tosi M, Alesse E, Ficorella C, Ricevuto E. Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx). BMC Med 2013;11:59. [PMID: 23497191 DOI: 10.1186/1741-7015-11-59] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
46 Huiskens J, van Gulik TM, van Lienden KP, Engelbrecht MR, Meijer GA, van Grieken NC, Schriek J, Keijser A, Mol L, Molenaar IQ, Verhoef C, de Jong KP, Dejong KH, Kazemier G, Ruers TM, de Wilt JH, van Tinteren H, Punt CJ. Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG). BMC Cancer 2015;15:365. [PMID: 25943574 DOI: 10.1186/s12885-015-1323-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
47 Lee RC, Kanhere H, Trochsler M, Broadbridge V, Maddern G, Price TJ. Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases? World J Gastrointest Oncol 2018; 10(8): 211-220 [PMID: 30147847 DOI: 10.4251/wjgo.v10.i8.211] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
48 Bonney GK, Chew CA, Lodge P, Hubbard J, Halazun KJ, Trunecka P, Muiesan P, Mirza DF, Isaac J, Laing RW, Iyer SG, Chee CE, Yong WP, Muthiah MD, Panaro F, Sanabria J, Grothey A, Moodley K, Chau I, Chan ACY, Wang CC, Menon K, Sapisochin G, Hagness M, Dueland S, Line PD, Adam R. Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. Lancet Gastroenterol Hepatol 2021;6:933-46. [PMID: 34506756 DOI: 10.1016/S2468-1253(21)00219-3] [Reference Citation Analysis]
49 Saez-Carlin P, García-Botella A, Diez-Valladares LI, Ortega Medina L, Méndez R, González JCM, Bernal I, Serrano García I, Avellana R, Torres García AJ. Splenic volume as a biomarker of hepatic damage after chemotherapy in patients with resected colorectal liver metastases (CRLM). Clin Transl Oncol 2020;22:1180-6. [PMID: 31758496 DOI: 10.1007/s12094-019-02245-1] [Reference Citation Analysis]
50 Snyder A, Kemeny N, Shamseddine A, Al-Olayan A, El-Merhi F, Kelsen DP, Jamali F, Sidani M, Mukherji D, El-Naghy M, O'Reilly EM, Saltz LB, Abou-Alfa GK. Liver-directed conversion therapy in metastatic colon cancer. J Gastrointest Oncol 2015;6:322-8. [PMID: 26029460 DOI: 10.3978/j.issn.2078-6891.2015.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Dueland S, Syversveen T, Solheim JM, Solberg S, Grut H, Bjørnbeth BA, Hagness M, Line P. Survival Following Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastases. Annals of Surgery 2020;271:212-8. [DOI: 10.1097/sla.0000000000003404] [Cited by in Crossref: 47] [Cited by in F6Publishing: 22] [Article Influence: 23.5] [Reference Citation Analysis]
52 Line PD, Dueland S. Liver transplantation for secondary liver tumours: The difficult balance between survival and recurrence. J Hepatol. 2020;73:1557-1562. [PMID: 32896581 DOI: 10.1016/j.jhep.2020.08.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
53 Bender U, Rho YS, Barrera I, Aghajanyan S, Acoba J, Kavan P. Adjuvant therapy for stages II and III colon cancer: risk stratification, treatment duration, and future directions. Curr Oncol 2019;26:S43-52. [PMID: 31819709 DOI: 10.3747/co.26.5605] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
54 Lang SA, Bednarsch J, Czigany Z, Joechle K, Kroh A, Amygdalos I, Strnad P, Bruns T, Heise D, Ulmer F, Neumann UP. Liver transplantation in malignant disease. World J Clin Oncol 2021; 12(8): 623-645 [PMID: 34513597 DOI: 10.5306/wjco.v12.i8.623] [Reference Citation Analysis]
55 Hoang T, Kim J. Combining Correlated Outcomes and Surrogate Endpoints in a Network Meta-Analysis of Colorectal Cancer Treatments. Cancers (Basel) 2020;12:E2663. [PMID: 32961943 DOI: 10.3390/cancers12092663] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Abrahamsson H, Jensen BV, Berven LL, Nielsen DL, Šaltytė Benth J, Johansen JS, Larsen FO, Johansen JS, Ree AH. Antitumour immunity invoked by hepatic arterial infusion of first-line oxaliplatin predicts durable colorectal cancer control after liver metastasis ablation: 8-12 years of follow-up. Int J Cancer 2020;146:2019-26. [PMID: 31872440 DOI: 10.1002/ijc.32847] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
57 Dueland S, Syversveen T, Hagness M, Grut H, Line PD. Liver transplantation for advanced liver-only colorectal metastases. Br J Surg 2021:znab196. [PMID: 34117498 DOI: 10.1093/bjs/znab196] [Reference Citation Analysis]
58 Cersosimo RJ. Management of advanced colorectal cancer, Part 1. Am J Health Syst Pharm. 2013;70:395-406. [PMID: 23413162 DOI: 10.2146/ajhp110532] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
59 Villard C, Westman J, Frank J, Jynge O, Sparrelid E, Jorns C. The potential use of extended criteria donors and eligible recipients in liver transplantation for unresectable colorectal liver metastases in Central Sweden. Hepatobiliary Surg Nutr 2021;10:476-85. [PMID: 34430526 DOI: 10.21037/hbsn.2020.03.10] [Reference Citation Analysis]
60 Smedman TM, Line PD, Hagness M, Syversveen T, Grut H, Dueland S. Liver transplantation for unresectable colorectal liver metastases in patients and donors with extended criteria (SECA-II arm D study). BJS Open. 2020;4:467-477. [PMID: 32333527 DOI: 10.1002/bjs5.50278] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
61 Pan DC, Krishnan V, Salinas AK, Kim J, Sun T, Ravid S, Peng K, Wu D, Nurunnabi M, Nelson JA, Niziolek Z, Guo J, Mitragotri S. Hyaluronic acid-doxorubicin nanoparticles for targeted treatment of colorectal cancer. Bioeng Transl Med 2021;6:e10166. [PMID: 33532580 DOI: 10.1002/btm2.10166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A. FOLFOXIRI plus bevacizumab vs FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306-1315. [PMID: 26338525 DOI: 10.1016/s1470-2045(15)00122-9] [Cited by in Crossref: 478] [Cited by in F6Publishing: 243] [Article Influence: 68.3] [Reference Citation Analysis]
63 Tong M, Liu H, Hao J, Fan D. Comparative pharmacoproteomics reveals potential targets for berberine, a promising therapy for colorectal cancer. Biochem Biophys Res Commun 2020:S0006-291X(20)30320-X. [PMID: 32087971 DOI: 10.1016/j.bbrc.2020.02.052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
64 Masi G, Fornaro L, Caparello C, Falcone A. Liver metastases from colorectal cancer: how to best complement medical treatment with surgical approaches. Future Oncology 2011;7:1299-323. [DOI: 10.2217/fon.11.108] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
65 Foss A, Lerut JP. Liver transplantation for metastatic liver malignancies. Curr Opin Organ Transplant 2014;19:235-44. [PMID: 24807212 DOI: 10.1097/MOT.0000000000000086] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
66 Kim S, Dobi E, Jary M, Monnien F, Curtit E, Nguyen T, Lakkis Z, Heyd B, Fratte S, Cléau D. Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels. BMC Cancer. 2013;13:611. [PMID: 24373251 DOI: 10.1186/1471-2407-13-611] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
67 Cartwright TH, Yim YM, Yu E, Chung H, Halm M, Forsyth M. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology. Clin Colorectal Cancer. 2012;11:238-246. [PMID: 22658457 DOI: 10.1016/j.clcc.2012.05.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
68 Xu W, Kuang M, Gong Y, Cao C, Chen J, Tang C. Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis. Onco Targets Ther 2016;9:4833-42. [PMID: 27536147 DOI: 10.2147/OTT.S104981] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
69 Ychou M, Rivoire M, Thezenas S, Guimbaud R, Ghiringhelli F, Mercier-Blas A, Mineur L, Francois E, Khemissa F, Chauvenet M, Kianmanesh R, Fonck M, Houyau P, Aparicio T, Galais MP, Audemar F, Assenat E, Lopez-Crapez E, Jouffroy C, Adenis A, Adam R, Bouché O. Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial. Br J Cancer 2022. [PMID: 34992255 DOI: 10.1038/s41416-021-01644-y] [Reference Citation Analysis]
70 Chua TC, Al-Alem I, Zhao J, Glenn D, Liauw W, Morris DL. Radiofrequency ablation of concomitant and recurrent pulmonary metastases after surgery for colorectal liver metastases. Ann Surg Oncol 2012;19:75-81. [PMID: 21710327 DOI: 10.1245/s10434-011-1859-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
71 Bruera G, Cannita K, Giordano AV, Vicentini R, Ficorella C, Ricevuto E. Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen. Int J Oncol 2014;44:1820-30. [PMID: 24715238 DOI: 10.3892/ijo.2014.2369] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
72 Cremolini C, Casagrande M, Loupakis F, Aprile G, Bergamo F, Masi G, Moretto R R, Pietrantonio F, Marmorino F, Zucchelli G, Tomasello G, Tonini G, Allegrini G, Granetto C, Ferrari L, Urbani L, Cillo U, Pilati P, Sensi E, Pellegrinelli A, Milione M, Fontanini G, Falcone A. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. European Journal of Cancer 2017;73:74-84. [DOI: 10.1016/j.ejca.2016.10.028] [Reference Citation Analysis]
73 Stragier E, Prenen H. Antiangiogenic therapies in colorectal cancer. memo 2017;10:213-7. [DOI: 10.1007/s12254-017-0359-8] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
74 Lévi FA, Boige V, Hebbar M, Smith D, Lepère C, Focan C, Karaboué A, Guimbaud R, Carvalho C, Tumolo S, Innominato P, Ajavon Y, Truant S, Castaing D, De Baere T, Kunstlinger F, Bouchahda M, Afshar M, Rougier P, Adam R, Ducreux M; Association Internationale pour Recherche sur Temps Biologique et Chronothérapie (ARTBC International). Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Ann Oncol 2016;27:267-74. [PMID: 26578731 DOI: 10.1093/annonc/mdv548] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 8.0] [Reference Citation Analysis]
75 Hurwitz HI, Tan BR, Reeves JA, Xiong H, Somer B, Lenz HJ, Hochster HS, Scappaticci F, Palma JF, Price R, Lee JJ, Nicholas A, Sommer N, Bendell J. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). Oncologist 2019;24:921-32. [PMID: 30552157 DOI: 10.1634/theoncologist.2018-0344] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
76 Allegra C, George T Jr, Yothers G. Multiagent regimens for metastatic colorectal cancer: if some is good, more must be better. J Natl Cancer Inst 2011;103:4-5. [PMID: 21123834 DOI: 10.1093/jnci/djq483] [Reference Citation Analysis]
77 Tai CC, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, Cheng HH, Chao Y, Teng HW. Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer. Am J Clin Oncol 2020;43:28-34. [PMID: 31693507 DOI: 10.1097/COC.0000000000000637] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
78 Moris D, Ronnekleiv-Kelly S, Kostakis ID, Tsilimigras DI, Beal EW, Papalampros A, Dimitroulis D, Felekouras E, Pawlik TM. Operative Results and Oncologic Outcomes of Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) Versus Two-Stage Hepatectomy (TSH) in Patients with Unresectable Colorectal Liver Metastases: A Systematic Review and Meta-Analysis. World J Surg. 2018;42:806-815. [PMID: 28798996 DOI: 10.1007/s00268-017-4181-6] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 10.8] [Reference Citation Analysis]
79 Bhatti T, Moser M, Tan KT, Chalchal H, Souied O, Le D, Shaw J, Zaidi A, Gill D, Ahmed S. Rate of Curative Surgery in Real-world Patients with Unresectable Metastatic Colorectal Cancer Treated with FOLFOXIRI ± Bevacizumab: A Western Canadian Province Experience. J Gastrointest Cancer 2021. [PMID: 33779898 DOI: 10.1007/s12029-021-00634-w] [Reference Citation Analysis]
80 Marques RP, Duarte GS, Sterrantino C, Pais HL, Quintela A, Martins AP, Costa J. Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017;118:54-62. [PMID: 28917269 DOI: 10.1016/j.critrevonc.2017.08.006] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 6.4] [Reference Citation Analysis]
81 Bhudia J, Glynne-Jones R, Smith T, Hall M. Neoadjuvant Chemotherapy without Radiation in Colorectal Cancer. Clin Colon Rectal Surg 2020;33:287-97. [PMID: 32968364 DOI: 10.1055/s-0040-1713746] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Rossi L, Vakiarou F, Zoratto F, Bianchi L, Papa A, Basso E, Verrico M, Lo Russo G, Evangelista S, Rinaldi G, Perrone-Congedi F, Spinelli GP, Stati V, Caruso D, Prete A, Tomao S. Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC). Cancer Manag Res. 2013;5:377-385. [PMID: 24399885 DOI: 10.2147/cmar.s47986] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
83 Sharma MR, Joshi SS, Karrison TG, Allen K, Suh G, Marsh R, Kozloff MF, Polite BN, Catenacci DVT, Kindler HL. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer. 2019;. [PMID: 30645764 DOI: 10.1002/cncr.31938] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
84 Tasoudis PT, Ziogas IA, Alexopoulos SP, Fung JJ, Tsoulfas G. Role of liver transplantation in the management of colorectal liver metastases: Challenges and opportunities. World J Clin Oncol 2021; 12(12): 1193-1201 [DOI: 10.5306/wjco.v12.i12.1193] [Reference Citation Analysis]
85 Zoetemelk M, Ramzy GM, Rausch M, Nowak-Sliwinska P. Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment. Molecules 2020;25:E2614. [PMID: 32512790 DOI: 10.3390/molecules25112614] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
86 Dueland S, Line PD, Hagness M, Foss A, Andersen MH. Long-term quality of life after liver transplantation for non-resectable colorectal metastases confined to the liver. BJS Open 2019;3:180-5. [PMID: 30957065 DOI: 10.1002/bjs5.50116] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
87 Guo M, Jin N, Pawlik T, Cloyd JM. Neoadjuvant chemotherapy for colorectal liver metastases: A contemporary review of the literature. World J Gastrointest Oncol 2021; 13(9): 1043-1061 [PMID: 34616511 DOI: 10.4251/wjgo.v13.i9.1043] [Reference Citation Analysis]
88 de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. Clin Pharmacokinet. 2018;. [PMID: 29520731 DOI: 10.1007/s40262-018-0644-7] [Cited by in Crossref: 90] [Cited by in F6Publishing: 78] [Article Influence: 30.0] [Reference Citation Analysis]
89 Dueland S, Grut H, Syversveen T, Hagness M, Line PD. Selection criteria related to long-term survival following liver transplantation for colorectal liver metastasis. Am J Transplant. 2020;20:530-537. [PMID: 31674105 DOI: 10.1111/ajt.15682] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
90 Atreya CE, Yaeger R, Chu E. Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches. Am Soc Clin Oncol Educ Book 2017;37:246-56. [PMID: 28561718 DOI: 10.1200/EDBK_175679] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 0.2] [Reference Citation Analysis]
91 Sunakawa Y, Bekaii-Saab T, Stintzing S. Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer. Cancer Treat Rev 2016;45:97-104. [PMID: 27002945 DOI: 10.1016/j.ctrv.2016.03.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
92 Ahmed S, Johnson K, Ahmed O, Iqbal N. Advances in the management of colorectal cancer: from biology to treatment. Int J Colorectal Dis 2014;29:1031-42. [PMID: 24953060 DOI: 10.1007/s00384-014-1928-5] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 5.5] [Reference Citation Analysis]
93 Bruera G, Cannita K, Di Giacomo D, Lamy A, Troncone G, Dal Mas A, Coletti G, Frébourg T, Sabourin JC, Tosi M, Ficorella C, Ricevuto E. Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease. BMC Med 2012;10:135. [PMID: 23136868 DOI: 10.1186/1741-7015-10-135] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
94 Kubal C, Mihaylov P, Holden J. Oncologic indications of liver transplantation and deceased donor liver allocation in the United States. Curr Opin Organ Transplant 2021;26:168-75. [PMID: 33650998 DOI: 10.1097/MOT.0000000000000866] [Reference Citation Analysis]
95 Bruera G, Russo A, Galvano A, Rizzo S, Ricevuto E. Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy. Oncotarget 2017;8:37875-83. [PMID: 28053287 DOI: 10.18632/oncotarget.14333] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
96 Fornaro L, Leone F, Vienot A, Casadei-Gardini A, Vivaldi C, Lièvre A, Lombardi P, De Luca E, Vernerey D, Sperti E, Musettini G, Satolli MA, Edeline J, Spadi R, Neuzillet C, Falcone A, Pasquini G, Clerico M, Passardi A, Buscaglia P, Meurisse A, Aglietta M, Brac C, Vasile E, Montagnani F. Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. Clin Colorectal Cancer 2019;18:e394-401. [PMID: 31564556 DOI: 10.1016/j.clcc.2019.08.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
97 Loupakis F, Cremolini C, Schirripa M, Masi G, Falcone A. Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer. Expert Opinion on Biological Therapy 2011;11:519-31. [DOI: 10.1517/14712598.2011.552882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
98 Cremolini C, Casagrande M, Loupakis F, Aprile G, Bergamo F, Masi G, Moretto R R, Pietrantonio F, Marmorino F, Zucchelli G, Tomasello G, Tonini G, Allegrini G, Granetto C, Ferrari L, Urbani L, Cillo U, Pilati P, Sensi E, Pellegrinelli A, Milione M, Fontanini G, Falcone A. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. European Journal of Cancer 2017;73:74-84. [DOI: 10.1016/j.ejca.2016.10.028] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
99 Fornaro L, Vasile E, Masi G, Loupakis F, Baldi GG, Allegrini G, Salvatore L, Cremolini C, Cupini S, Cortesi E, Tuzi A, Granetto C, Brunetti IM, Ricci S, Falcone A. Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen. Clin Colorectal Cancer 2012;11:71-6. [PMID: 21903485 DOI: 10.1016/j.clcc.2011.06.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]